Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Anemia in Patients with Chronic Kidney Disease: A Pre-Post Observational Analysis - PubMed
4 hours ago
- #Chronic Kidney Disease
- #SGLT2 inhibitors
- #Anemia
- SGLT2 inhibitor therapy (empagliflozin or dapagliflozin) over 18 months was associated with a modest increase in hemoglobin levels in patients with chronic kidney disease.
- Unadjusted ferritin levels decreased slightly, but after adjustment for inflammatory and nutritional status, ferritin remained unchanged, indicating stable iron metabolism.
- There was no significant difference in hematologic effects between empagliflozin and dapagliflozin, but baseline kidney function, proteinuria, iron status, and sex influenced outcomes.
- The study design, a pre-post observational analysis without a control group, limits causal inference, but suggests potential favorable effects of SGLT2is on anemia parameters.